![](/img/cover-not-exists.png)
Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions
Umehara, Kenichi, Huth, Felix, Jin, Yi, Schiller, Hilmar, Aslanis, Vassilios, Heimbach, Tycho, He, HandanLanguage:
english
Journal:
Drug Metabolism and Personalized Therapy
DOI:
10.1515/dmpt-2018-0042
Date:
May, 2019
File:
PDF, 758 KB
english, 2019